Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846052 · ClinicalTrials.gov registry record
Clinical and Genetic Characterization of Individuals With Achromatopsia
A clinical trial of Achromatopsia, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- 56
- Enrollment target
- 5
- Study locations
NCT01846052: Completed study of Achromatopsia, sponsored by Beacon Therapeutics.
NCT01846052 is a study of Achromatopsia that has completed, run by Beacon Therapeutics. The registered enrollment target is 56 participants, below the 6,685-participant average among 3 other Achromatopsia trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01846052, a study of Achromatopsia, has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.
Primary Outcome
Visual acuity will be measured by EVA or ETDRS methods
Conditions Studied
Study Locations (5)
Florida
- VitreoRetinal Associates - Gainesville
- Bascom Palmer Eye Institute - Miami
Illinois
- Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp - Chicago
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-06 |
| Est. Completion | 2017-04 |
What the finished NCT01846052 record still lists
NCT01846052 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 6,685-participant average among 3 other Achromatopsia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Achromatopsia appearing as the primary indexed condition, and to 0 interventions.
NCT01846052 lists 5 locations in 4 states (Florida, Illinois, Oregon).
Frequently Asked Questions
What is clinical trial NCT01846052 about?
NCT01846052 is a clinical study titled "Clinical and Genetic Characterization of Individuals With Achromatopsia". The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.
What is the current status of trial NCT01846052?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2013-06. Estimated completion is 2017-04.
What conditions does trial NCT01846052 study?
This clinical trial studies the following conditions: Achromatopsia.
Who is sponsoring clinical trial NCT01846052?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01846052 being conducted?
This trial has 5 study locations across Florida, Illinois, Oregon, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achromatopsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia